264 related articles for article (PubMed ID: 30616534)
1. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.
Tomita Y; Uemura H; Oya M; Shinohara N; Habuchi T; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Rini BI
BMC Cancer; 2019 Jan; 19(1):17. PubMed ID: 30616534
[TBL] [Abstract][Full Text] [Related]
2. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
3. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
4. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
6. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N;
Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135
[TBL] [Abstract][Full Text] [Related]
7. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
8. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma.
Kameda T; Takayama T; Sugihara T; Takeshima S; Yamazaki M; Komatsubara M; Kamei J; Fujisaki A; Ando S; Kurokawa S; Fujimura T
Asia Pac J Clin Oncol; 2020 Aug; 16(4):241-246. PubMed ID: 32129940
[TBL] [Abstract][Full Text] [Related]
11. Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.
Rini BI; Tomita Y; Melichar B; Ueda T; Grünwald V; Fishman MN; Uemura H; Oya M; Bair AH; Andrews GI; Rosbrook B; Jonasch E
Clin Genitourin Cancer; 2016 Dec; 14(6):499-503. PubMed ID: 27236772
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
13. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
14. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
[TBL] [Abstract][Full Text] [Related]
15. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V
Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
[TBL] [Abstract][Full Text] [Related]
16. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
[TBL] [Abstract][Full Text] [Related]
17. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
19. Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study.
Oya M; Tomita Y; Fukasawa S; Shinohara N; Habuchi T; Rini BI; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Uemura H
Cancer Sci; 2017 Jun; 108(6):1231-1239. PubMed ID: 28267243
[TBL] [Abstract][Full Text] [Related]
20. [Treatment Outcome of Axitinib for Metastatic Renal-Cell Carcinoma Patients].
Kusakabe N; Osawa T; Miyata H; Kikuchi H; Matsumoto R; Maruyama S; Abe T; Shinohara N
Hinyokika Kiyo; 2018 Sep; 64(9):353-358. PubMed ID: 30369225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
